OasisLMS

Pulmonary hypertension (PH) continues to pose significant diagnostic and therapeutic challenges. Timely and accurate diagnosis is crucial for initiating appropriate therapy to improve patient outcomes. Delayed diagnosis is common, with patients often presenting in advanced stages, partly due to the nonspecific nature of early symptoms like dyspnea and fatigue.

This seminar is designed to provide updates on the latest advances in the diagnosis, classification, and management of pulmonary hypertension, with an emphasis on the most recent recommendations from the 2022 ESC/ERS Guidelines.

Following this activity, participants will be better able to:

Part 1- Group 1: Epidemiology, Diagnosis, and Risk Stratification of PAH (Tom Cascino, MD)

1. Review the clinical and hemodynamic classifications of PH with a focus on the epidemiology
2. Apply a systematic diagnostic approach to evaluating dyspnea and suspected PH
3. Understand the practical application of risk stratification in PAH, including its limitations

Part 2- Group 1: Pharmacotherapy for PAH including the new kid on the block (Kevin Kissling, PharmD)

1. Apply current treatment algorithms to select initial pharmacotherapy regimens and guide adjustment according to response
2. Examine implementation of the activin signaling inhibitor sotatercept as the fourth treatment pathway in pulmonary hypertension

Part 3- Group 2: Pulmonary Hypertension in Left Heart Disease-what do we know and where are we headed? (Ashley Hardin, MD)

1. Understand the definition and classification of group 2 PH
2. Describe the shift toward disaggregating underlying etiologies of group 2 PH and staging PH due to left heart disease
3. Discuss recommendations for the treatment of group 2 PH including the role of pulmonary vasodilators and provocative testing

Part 4- Group 4: Chronic Thromboembolic Pulmonary Hypertension-diagnosis and management including surgical and percutaneous treatment options (Jennifer Ashby, NP)

1. Identify patients at risk for CTEPH based on clinical history, symptoms, and risk factors
2. Recognize that CTEPH is a rare but potentially curable form of pulmonary hypertension arising from unresolved or recurrent pulmonary embolism
3. Discuss the role of lifelong anticoagulation
4. Review surgical and interventional options for CTEPH and when to refer to a Comprehensive Center of Care

• Elizabeth Ashley Hardin, MD
• Kevin Kissling, PharmD
• Thomas Matthew Cascino, MD, MSc
• Jennifer Ashby, MSN, RN, ACNP-BC

Group 1: Epidemiology, Diagnosis, and Risk Stratification of PAH
Thomas Matthew Cascino, MD, MSc

Group 1: Pharmacotherapy for PAH including the new kid on the block
Kevin Kissling, PharmD             
 
Group 2: Pulmonary Hypertension in Left Heart Disease-what do we know and where are we headed?
Elizabeth Ashley Hardin, MD    

Group 4: Chronic Thromboembolic Pulmonary Hypertension-diagnosis and management including surgical and percutaneous treatment options 
Jennifer Ashby, MSN, RN, ACNP-BC

Panel Discussion

Closing Remarks

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest: 

• Thomas Matthew Cascino, MD, MSc - Consultant: Merck, Abbott, Johnson & Johnson
• Kevin Kissling, PharmD - Nuwellis

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for PHarmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum of 1.50 contact hours.

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE.  ACPE Universal Activity Numbers (UAN): JA4008267-0000-25-007-L01-P (live attendance only); JA4008267-0000-25-008-H01-P (on-demand/home study).

The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity is approved for 1.50 contact hours (0.15 CEUs) of general continuing education for health care professionals.

Successful completion of this activity includes the completion of the post-course evaluation.